Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 15/20 | 0.60 |
| ▸ | TNF | P01375 | 3/20 | 0.31 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.30 |
| ▸ | SCN1A | P35498 | 1/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22843458 | 0.94 | NT5E (0.53) | NT5ETNF | |
| SCHEMBL22843613 | 0.91 | NT5E (0.50) | NT5E | |
| SCHEMBL22843558 | 0.90 | NT5E (0.49) | NT5E | |
| SCHEMBL22843594 | 0.90 | NT5E (0.49) | NT5E | |
| SCHEMBL22866583 | 0.89 | NT5E (0.62) | NT5ETNFGGPS1 | |
| SCHEMBL22843457 | 0.89 | NT5E (0.59) | NT5EGGPS1 | |
| SCHEMBL22843499 | 0.88 | NT5E (0.59) | NT5E | |
| SCHEMBL22843493 | 0.88 | NT5E (0.59) | NT5E | |
| SCHEMBL22843481 | 0.80 | NT5E (0.47) | NT5E | |
| SCHEMBL22866535 | 0.79 | NT5E (0.52) | NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200405629-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | ARCUS BIOSCIENCES, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405629-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | NT5C2, ADA, ENTPD1 | NT5E 10/4885TNF 1354/4885GGPS1 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.